The United States and United Kingdom Announce Duty-Free Arrangement on Medicines.
The United Kingdom and the United States have secured a significant bilateral deal that will ensure no levies on British drug products being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that tariffs on these key goods will remain at nothing for a duration of three years.
This agreement follows recent threats to dramatically increase duties on branded drug products, with figures mentioned as high as double the cost.
"This arrangement with the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. drug exports," an announcement noted.
Commercial Significance
Medicines constitute one of the UK's most significant export categories to the United States, which is clearly the largest buyer for large UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK exported medicines totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures employment, stimulates investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The pact involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments topped 20%.
Industry Background
The deal follows a long-running tension between the sector and the ministers over medicine costs and regulatory access.
This friction were exacerbated by claims that US customers were paying a premium for the same drugs than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while substantial investments have been pledged toward US facilities.
One official acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
